Introduction {#s0005}
============

Leishmaniasis is listed as one of the eight neglected tropical diseases by the World Health Organization (WHO), and the number of cases in endemic areas has significantly increased in recent years ([@bb0110]). The increase is caused by unicellular parasites that are injected into the skin by small, flying insects ([Fig. 1](#f0005){ref-type="fig"}; [@bb0130]).Fig. 1Sand fly (Phlebotomus) content provider (Source: <https://de.wikipedia.org/wiki/Datei:Phlebotomus_pappatasi_bloodmeal_continue2.jpg>)Fig. 1

The only proven vectors of human disease are sandflies, the species of genus *Phlebotomus* in the Old World and *Lutzomyia* in the New World ([@bb0265], [@bb0315]). Transmission is by the vector, which transmits the disease from infected to healthy humans (anthroponotic infection) or from an animal reservoir to humans (zoonotic infection; [@bb0265]). Sandflies mostly show maximum activity in warm weather (summertime) and clear nights with low wind speed ([@bb0230]).

Leishmaniasis is currently endemic to 102 countries/areas according to the WHO ([@bb0295], [@bb0325]). Mortality and morbidity from leishmaniasis is estimated at 2 to 4 million disability-adjusted life years worldwide ([@bb0295], [@bb0310]). Leishmaniasis causes different clinical syndromes that are determined by the balance between parasitic factors (e.g., tropisms, virulence, resistance, species) and the host--immune response ([@bb0080]). There are four main forms of the disease: visceral leishmaniasis (VL, also known as kala-azar); post--kala-azar dermal leishmaniasis (PKDL); cutaneous leishmaniasis (CL); and mucocutaneous leishmaniasis (MCL; [@bb0325]). Twelve countries (Afghanistan, Algeria, Brazil, Colombia, Iran, Morocco, Pakistan, Saudi Arabia, Syria, Peru, Tunisia, and Turkey) were identified as having a high burden (\> 2500 cases per year) of CL by the [@bb0325]. On the other hand, 13 countries were identified as high burden for VL: Bangladesh, Brazil, China, Ethiopia, India, Kenya, Nepal, Paraguay, Somalia, South Sudan, Spain, Sudan, and Uganda ([@bb0325]).

Currently, leishmaniasis is increasingly seen among migrants, travelers, ecotourists, and military personnel. Recent outbreaks of leishmaniasis could be due to increased human migration because of violent conflicts (e.g., in Syria) that cause the introduction of disease to newer surroundings ([@bb0095], [@bb0230]). Furthermore, *Leishmania* has increasingly been seen as an opportunistic pathogen of HIV-infected adults ([@bb0030], [@bb0110]). It is a challenge especially in nonendemic regions because experience with the diagnosis and management of the disease is limited.

Clinical manifestation {#s0010}
======================

People who have not previously had the disease are susceptible to CL. Cutaneous lesions can either be a single, limited skin lesion or multiple, large, locally destructive skin lesions ([@bb0060]). Clinical lesions appear after an incubation period, which often can be many months. Spontaneous healing often results in lifelong immunity ([@bb0295]). CL lesions usually develop on body parts that are mainly open and exposed to the environment, such as the face, forearms, and lower legs. The disease generally presents as a painless, brownish, erythematous papule after a long (2-8 months) incubation period. Infection mainly occurs during the summer months, which causes the disease to appear later during the winter months. These newly appearing papules then gradually enlarge, turning into a nodule or plaque within 6 months ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Newly appeared cutaneous leishmaniasis papuleFig. 2

Subsequently, these indurated nodules usually ulcerate from their center, and a brownish crust (tightly adhered to the base) covers the infection area and ulcer. The most distinctive clinical picture of CL is the appearance of sloping, firm margins with a prominent central crater of the ulcer, called volcanic ulcer. This which can help differentiate CL from other causes of chronic ulcer ([Fig. 3](#f0015){ref-type="fig"}). Wet-type CL, which is caused by *L. major*, has a shorter incubation period (˂2 months) and a shorter time to self-cure (˂6 months) than the dry type ([@bb0295]). These limited lesions usually heal spontaneously, leaving a depressed scar.Fig. 3Indurated nodule with central ulcer and brownish crust (tightly adhered to the base) covering the ulcerFig. 3

Because of its mimicking nature, CL is called the great imitator and can mislead practitioners because of clinical manifestations that mimic malignant tumors (e.g., basal or squamous cell carcinomas with nodular or nodulo-ulcerative lesions), erysipelas, eczema, sporotrichosis, lupus vulgaris, psoriasis, atypical mycobacterial infections, and other deep fungal infections ([Fig. 4](#f0020){ref-type="fig"}; [@bb0005], [@bb0145], [@bb0280], [@bb0285], [@bb0295]).Fig. 4Different clinical manifestations of cutaneous leishmaniasis, mimicking a wide range of dermatological diseasesFig. 4

CL should be considered in differential diagnoses of patients with a history of living in endemic areas or a history of travel to an endemic region, 1 to 6 months before the lesion appears. Although CL occurs in patients of all ages, onset is more common in children and young individuals ([@bb0295]).

VL is the most severe form of leishmaniasis and is characterized by prolonged fever, splenomegaly, hepatomegaly, pancytopenia, progressive anemia, and weight loss. Fortunately, VL rarely occurs, and these patients often have underlying immunosuppression. If left untreated, VL is often fatal ([@bb0060], [@bb0265]).

PKDL occurs in 5% to 15% of endemic areas of VL, such as South Asia and East Africa, as a consequence of VL ([@bb0175], [@bb0335]). PKDL is not fatal, and patients do not feel ill; thus, patients are not usually in search of treatment. However, PKDL lesions are reservoirs for leishmaniasis transmission ([@bb0035]). PKDL can be seen as hypopigmented macules and patches, erythematous papules and nodules, or mixed polymorphic forms of these lesions ([@bb0175]). Lesions usually start as a single or few macular lesions that gradually increase in size and distribution. Differential diagnoses include pityriasis versicolor, pityriasis alba, vitiligo, leprosy, discoid lupus erythematosus, and lupus vulgaris ([@bb0320]). Treatment should be with systemic therapies.

Cutaneous leishmaniasis in women {#s0015}
================================

Permanently disfiguring scars caused by CL and PKDL create a lifelong stigma for individuals ([Fig. 5](#f0025){ref-type="fig"}; [@bb0330]). A recent review by [@bb0045] investigated the current knowledge of the psychological burden and stigma related to CL by evaluating several reports in electronic databases. The researchers found that quantitative assessments using standard scales and qualitative research suggest that CL is a source of psychological suffering, stigmatization, and decreased quality of life (QoL).Fig. 5Permanent disfiguring scar on the face can create a lifelong stigma for individualsFig. 5

In a study by [@bb0300], CL had the maximum effect on patients' QoL regarding symptoms and emotions, such as embarrassment or self-consciousness, according to the Dermatology Life Quality Index. In the study, patients with lesions that had an ulcerous appearance had a lower QoL. On the other hand, patients with papular lesions had a higher QoL, which was attributed to the papular lesions' natural qualities, such as being usually smaller than other lesions and seen more frequently in early stages of the disease.

However, CL is especially detrimental for women and young girls in poor, uneducated, and underprivileged societies because of isolation and exclusion of these women from all aspects of life, such as education, business, and social activities ([Fig. 6](#f0030){ref-type="fig"}). In some areas, women are considered most exposed to mosquito bites because they usually have more active roles in farming activities, taking care of cattle, and dealing with manure and waste ([@bb0040]). Studies in Pakistan and Afghanistan suggested that the number and visibility of CL scars is the determining factor for the level of stigma and social exclusion suffered by patients with CL. Especially affected girls and women generally believe that CL considerably alters their natural beauty and reduces their prospects of employment, marriage, and being valued in society ([@bb0065], [@bb0215]).Fig. 6Leishmaniasis scars can cause isolation and exclusion of the individual, resulting in significant alteration in psychological, social, and economic well-beingFig. 6

This was more prominent in patients of a young age who tended to experience more stigma ([@bb0070]) The results of the study by Chahed et al. also pointed out that the nature of the stigma experienced is associated with certain general fears and anticipation of rejection, sometimes even unrelated to the patient's true experience from society. The researchers suggested that the disability associated with the disfigurement depends on how patients see themselves in their own environment (i.e., personal, social, and professional; [@bb0070]). However, this is different in some countries, such as Pakistan or in Afghanistan, where young girls and women experience dire consequences in marriage and family life; they are particularly victimized as unacceptable for marriage, sometimes by their own families. Moreover, these women are usually separated from their children by their family during the disease and are not allowed to breastfeed or spend time with their children because they are thought to be a source of contamination ([@bb0040], [@bb0215], [@bb0250]).

In rural societies, unaffected women usually remain polite with young women who are affected by CL by sharing household chores or social activities, but even they do not agree to allow their sons to marry these affected young women. Others feel uncomfortable sharing meals with somebody with open sores, mostly for fear of contamination ([@bb0040]). In their study, Bennis et al. also found that the psychosocial impact of CL was more severe than that of acne and similar to that of scar tissue from burns.

In contrast, in Suriname, where CL mainly affects men, the only factor that generated stigma was the presence of a big (or multiple) CL lesion(s), but no barriers to marriage were observed ([@bb0210]). In a cross-sectional study by [@bb0250], 270 women were selected using the probability cluster sampling method at a 95% confidence interval to investigate the prevalence and predictors of mental disorders among women in Sanliurfa, Southeastern Turkey. The study results revealed that the frequency of any mental disorder was significantly different according to the history of previous trauma; anemia, history of leishmaniasis; domestic violence including physical, verbal, and economic; economic situation; and participation in decisions at home (*P* = .05).

Cutaneous leishmaniasis has long been endemic to Sanliurfa and is called a beauty scar. In the study by Yanik et al., patients with CL had more psychiatric problems, such as anxiety and depression, as well as reduced self-body satisfaction ([@bb0330]). The researchers found that patients with CL who have active lesions also have a lower QoL score than others. CL lesions on exposed body parts such as the face and hands, active CL for \> 1 year, permanent scar formation, and social stigmatization cause anxiety, depressive symptoms, and decreased body satisfaction and QoL in patients with CL.

All these studies and reports show the high burden of CL on women and women's health.

Diagnosis {#s0020}
=========

Considering leishmaniasis in the differential diagnoses is the most important step for medical practitioners. They need to confirm the diagnosis using one of the laboratory methods (e.g., dermal scraping smear, culture, incisional biopsy, or polymerase chain reaction \[PCR\]; [@bb0295]). The most commonly used laboratory method, especially in endemic areas, is the smear, which is a simple and inexpensive diagnostic tool ([@bb0105], [@bb0295]). Performing a slit-skin smear at the margin of the CL lesion increases the sensitivity of the smear. The smear is stained with Giemsa or Wright stain and then examined with direct microscopy ([Fig. 7](#f0035){ref-type="fig"}). In slit-skin smears, although papulonodular PKDL lesions are usually positive, macular lesions often fail to show parasites ([@bb0320]).Fig. 7In the case of the papular or nodular cutaneous leishmaniasis lesions, a longitudinal incision should be made with a scalpel (no: 15), followed by a dermal scraping. Subsequently, the scraped dermal material is spread out on a microscope slide, and the smear slide is stained with Giemsa or Wright stain for examination with direct microscopyFig. 7

*Leishmania* amastigotes are ellipsoid-shaped parasites that are 2 to 4 μm in length, with an eccentric nucleus and paranuclear kinetoplast in the cytoplasm of macrophages or extracellularly ([Fig. 8](#f0040){ref-type="fig"}). Many parasites within the cytoplasm of the macrophages may appear in the formation of a swarm of bees ([@bb0295]).Fig. 8Leishmania amastigotes with eccentric nucleus and paranuclear kinetoplast in a "swarm of bees" formation.Fig. 8

Cultures from an exudate, fine-needle aspirate or scraping also show good results. The gold standard medium for culture is Novy--MacNeal--Nicolle testing with positive results in 1 to 3 weeks, or Schneider Drosophila medium, which gives positive results in 1 week ([@bb0120]). Incisional skin biopsy with staining and culture is important to rule out cutaneous tuberculosis, atypical mycobacterial infections, and deep fungal infections where the clinician is not sure about the diagnosis.

Serological testing based on the detection of anti-*Leishmania* antibodies in patient serum and agglutination of the parasite is also used and are particularly valuable in VL and MCL ([@bb0230]). *Leishmania* parasites that cause CL can now be genotyped with PCR techniques to detect *Leishmania* DNA. Immunologic tests cannot distinguish between current and past infections. However, PCR-based methods are considered more specific and can detect current infections ([@bb0075], [@bb0115], [@bb0230]). PCR offers a rapid, highly sensitive, and specific modality of diagnosis and provides *Leishmania* species--specific treatment.

Treatment {#s0025}
=========

Due to the absence of a vaccine and the emergence of drug resistance, leishmaniasis continues to be a burden on endemic countries. Additionally, with increased migration, there is a significant chance that leishmaniasis could spread to other areas, introducing the pathogen to newer environments and leading to mutations and the emergence of more virulent subtypes ([@bb0230]). There is a need to report and document cases from endemic and nonendemic regions that can give information about disease distribution ([@bb0230], [@bb0255]).

For treatment, one should consider the clinical type of the disease, the *Leishmania* species involved, and the geography of infection. The main aims of CL treatment are to accelerate the healing process and to prevent complications (e.g., ugly scars), development of dysfunction, spreading, and recurrence of lesions ([@bb0220], [@bb0295]).

Per the Turkish guidelines, confirmed CL lesions (\< 1 cm in diameter) that are located on covered body areas can be left untreated, but practitioners must keep in mind that untreated patients can also be a source of the disease. The main indications for the treatment of CL are accepted as follows: cosmetically unacceptable lesions; persistent lesions; large lesions; lesions on the joints or face; multiple lesions; lesions located in the mucosa or near the lips, eyelids, or intranasal areas; lesions accompanied by nodular lymphangitis; psychologically affected patients; and patients with immunodeficiencies ([@bb0295]).

First-line therapy {#s0030}
==================

Pentavalent antimonials {#s0035}
-----------------------

Pentavalent antimonials (SbV) are the first-line therapy and have been widely used for \> 70 years ([@bb0230]). SbV is available as sodium stibogluconate (Pentostam) and meglumine antimoniate (Glucantime; [@bb0265]). Glucantime can be administered intramuscularly or intralesionally (IL), and sodium stibogluconate can be administered intravenously or IL ([@bb0295]). IL therapy is a suitable option for acute lesions that are noninflammatory and not very large (\< 4 cm in diameter) because this administration method has limited side effects ([@bb0275], [@bb0295]). Although systemic side effects are rarely seen in IL treatment, injections are better performed in a procedure room where practitioners can intervene against possible anaphylactic reaction ([@bb0295]). IL therapy should be considered first when a patient has contraindications to systemic therapy ([@bb0055], [@bb0295]). The drug is administered directly into the lesion with a fine-needle (27-30 gauge) syringe, such as an insulin syringe. The entire lesion must be blanched (optimal dose) to reach an effective dose of the drug in the lesion area (1-5 mL per session every 3-7 days; [@bb0295]).

SbV is administered systemically with a dose of 20 mg/kg/day for 20 days for CL and 28 to 30 days for MCL ([@bb0265]). After appropriate treatment, the recurrence rate is \< 2% ([@bb0245], [@bb0295]). Arthralgia, myalgia, and elevated hepatic and pancreatic enzymes are common adverse events, and major side effects are cardiac arrhythmia (prolonged QTc interval: \> 0.5 seconds), ventricular premature beats, ventricular tachycardia, and torsades de pointes ([@bb0265]). Side effects appear to be dose related and more common in patients with renal and liver impairment and those with cardiac arrhythmias. On the other hand, careful follow-up is important during treatment with systemic therapy, and hospitalization of these patients is usually needed to monitor the side effects.

Failure of treatment is often associated with inappropriate doses (below the therapeutic doses, which is ˂10 mg/kg/day, or insufficient dose due to obesity) and insufficient treatment duration (˂10 days; [@bb0240], [@bb0295]).

Other therapies {#s0040}
===============

Cryotherapy {#s0045}
-----------

Cryotherapy with liquid nitrogen (--195°C) is used once or twice weekly up to 6 weeks and has been found 95% effective in Israel, Greece, and Jordan but less effective (77%) in Turkey ([@bb0055], [@bb0150], [@bb0240], [@bb0245], [@bb0265], [@bb0290], [@bb0295]). The most effective application method is a double freeze-thaw cycle of 10 to 25 seconds, including a 2-mm healthy area from the lesion border ([@bb0150], [@bb0295]). The main disadvantage of this therapy is the high relapse rate (12%; [@bb0245], [@bb0290], [@bb0295]). Also, permanent hypopigmentation can be seen in patients with darker skin.

Thermotherapy {#s0050}
-------------

*Leishmania* parasites do not multiply at temperatures \> 39°C in vitro. Thermotherapy (i.e., burn the boil at 50°C for 30 seconds) with radiofrequency waves has been most commonly administered both for Old and New World CL with azoles ([@bb0265]).

Azoles {#s0055}
------

Azoles (e.g., ketoconazole, fluconazole, and itraconazole) act as inhibitors for ergosterol synthesis of *Leishmania* parasites ([@bb0265]) and have been used in the treatment of CL and MCL ([@bb0015], [@bb0020], [@bb0025], [@bb0100], [@bb0130], [@bb0170], [@bb0185], [@bb0190], [@bb0235], [@bb0305]). However, their efficacy is still unclear ([@bb0130], [@bb0185]). Azole benefits are their oral administration and fewer side effects. According to Turkish experience, ketoconazole at a dosage of 600 mg/day for 6 weeks can be used as an option in patients who are resistant or have severe side effects and risk to SbV therapy ([@bb0295]).

(Liposomal) Amphotericin B {#s0060}
--------------------------

Amphotericin B has been used in antimony-resistant cases but is mostly used for refractory VL in India. Amphotericin B is the only anti-*Leishmania* drug without drug-resistance ([@bb0155], [@bb0295]), but it has serious adverse effects, including infusion reactions, nephrotoxicity, hypokalemia, and myocarditis. However, the liposomal form is considered safer ([@bb0265]), and treatment with 3 mg/kg/day for 5 consecutive days and a sixth dose on day 10 (cumulative dose not exceeding 18 mg/kg) has been suggested for CL ([@bb0295], [@bb0260]). The drug should be administered as a slow infusion that lasts 30 to 60 minutes ([@bb0295]).

Paromomycin {#s0065}
-----------

Paromomycin is an aminoglycoside antibacterial drug that also has therapeutic effects against leishmania parasites. There are two available forms: parenteral and 15% topical formulations (Leishcutan; [@bb0090], [@bb0200], [@bb0295]). Paromomycin can be used twice a day for 10 to 20 days as an alternative to IL SbV therapy ([@bb0055], [@bb0295]).

Miltefosine {#s0070}
-----------

Miltefosine (Impavido), a phosphocholine analogue, is a new drug for VL ([@bb0050], [@bb0295]). Miltefosine is used 150 mg/day for 28 days ([@bb0055]). Its main advantages are the oral administration of the drug and the absence of serious side effects ([@bb0050], [@bb0295]). The main disadvantages are the expense of the therapy and its availability in a small number of countries.

Pentamidine {#s0075}
-----------

Pentamidine (Pentacarinat) is the first-line treatment for *L. guyanensis* infections ([@bb0055], [@bb0090], [@bb0295]), and is commonly used in New World CL and in MCL. Pentamidine is administered 2 to 4 mg/kg/day, for a total of 4 to 7 doses (IM or IV; maximum 300 mg/day; [@bb0295]). It should be administered by IV or injected slowly (IM) with a long needle (50 mm; [@bb0055]). Fasting glycemia, creatinine kinase, urine for proteinuria and glycosuria, blood pressure, and heart rate must be checked before every injection ([@bb0055], [@bb0125], [@bb0160]).

The efficacy and required dosage of anti-leishmanial agents vary in different areas; therefore, the WHO report with regard to treatment recommendations based on regional differences should be consulted ([@bb0265], [@bb0315]).

Follow-up {#s0080}
---------

The decrease in elevated lesions to the skin level and the healing of ulcerated lesions are considered complete healing ([@bb0295]). In CL, lesions should show signs of clinical improvement after 4 to 6 weeks. Complete healing with or without scar formation must be achieved within 3 to 6 months of treatment ([@bb0130]). Patients should be evaluated for a second cure treatment if there is no complete healing during the follow-up period ([@bb0295]).

In MCL, complete healing is expected during a 12-month follow-up period ([@bb0130]). Relapses can occur after treatment, and patients should be checked every 3 months over a 1-year period ([@bb0275], [@bb0295]).

Treatment during pregnancy and lactation {#s0085}
----------------------------------------

During pregnancy, larger CL lesions with different and/or exophytic clinical presentations are characteristic. There is no therapy to cure VL or PKDL during pregnancy, but a postpartum cure has been found to be complete with treatment ([@bb0180]). Unfortunately, an infection of VL might result in vertical transmission and fetal loss when treatment failure occurs ([@bb0180], [@bb0205]). Physical treatment methods, such as cryotherapy or thermotherapy, can be performed if necessary for CL during pregnancy and lactation ([@bb0165], [@bb0295]).

Co-infection with HIV {#s0090}
---------------------

HIV infection is most commonly seen with VL. However, some case reports also describe CL and HIV co-infections, which are seen increasingly ([@bb0135], [@bb0140], [@bb0195], [@bb0270]). CL lesions in HIV-co-infected individuals are usually atypical, and multiple or widespread lesions are due to immunodeficiency. However, the main risk is the development of VL in endemic areas in HIV-infected individuals. Furthermore, HIV co-infection prohibits an adequate therapeutic response and increases the risk of relapse ([@bb0010]). For treatment, HIV-infected patients also have a good response to antimonial therapies and liposomal amphotericine B ([@bb0225], [@bb0335]).

Prevention {#s0095}
----------

The use of long-lasting insecticide-treated nets (there are two products, PermaNet and Olyset generic, that are approved by the WHO) are the most suggested method of personal protection. Furthermore, insecticide spraying should be applied regularly indoor and outdoor ([@bb0085], [@bb0240], [@bb0295]).

Conclusions {#s0100}
===========

With the increase of human migration, every practitioner should be aware of this disease and keep this diagnosis in mind during their daily practice. This approach might help, especially with female patients. Leishmaniasis has detrimental effects on every aspect of women's lives, and early diagnosis and treatment can prevent dire consequences for women.
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